Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The heart of the World. Glob Heart. 2024;19(1):11.

Article  PubMed  PubMed Central  Google Scholar 

Mortensen MB, Dzaye O, Botker HE, Jensen JM, Maeng M, Bentzon JF, et al. Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the western Denmark heart registry. Circulation. 2023;147(14):1053–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruscica M, Bertoletti A, Gobbi C, Sirtori CR, Carugo S, Corsini A. Lipid-lowering approaches to manage statin-intolerant patients. Eur Heart J Suppl. 2024;26(Suppl 1):i56–9.

Article  PubMed  PubMed Central  Google Scholar 

Bays HE. Cholesterol-lowering drugs: Focus on Ezetimibe: cholesterol-lowering drugs: focus on ezetimibe. Eur Atherosclerosis J. 2022;1(1):14–24.

Article  Google Scholar 

Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–94.

Article  CAS  PubMed  Google Scholar 

Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004;47(1):1–9.

Article  CAS  PubMed  Google Scholar 

Pirillo A, Catapano AL. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):161–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Are we using Ezetimibe as much as we should? Biomark Insights. 2024;19:11772719241257410.

Article  PubMed  PubMed Central  Google Scholar 

Davis HR Jr., Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-pick C1 like 1 [NPC1L1). Atheroscler Suppl. 2008;9(2):77–81.

Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol. 2011;73:239–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao J, Dong LW, Liu S, Meng FH, Xie C, Lu XY, et al. Bile acids-mediated intracellular cholesterol transport promotes intestinal cholesterol absorption and NPC1L1 recycling. Nat Commun. 2023;14(1):6469.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radhakrishnan A, Sun LP, Kwon HJ, Brown MS, Goldstein JL. Direct binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domain. Mol Cell. 2004;15(2):259–68.

Article  CAS  PubMed  Google Scholar 

Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, Davis MA, et al. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem. 2006;281(10):6616–24.

Article  CAS  PubMed  Google Scholar 

Chang TY, Chang C. Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metab. 2008;7(6):469–71.

Article  CAS  PubMed  Google Scholar 

Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27.

CAS  PubMed  PubMed Central  Google Scholar 

Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.

Article  CAS  PubMed  Google Scholar 

Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data Brief. 2014(177):1–8.

Olsson AG. A new statin: a new standard. Clin Cardiol. 2001;24(8 Suppl):III18–23.

CAS  PubMed  Google Scholar 

Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001;111(3):185–91.

Article  CAS  PubMed  Google Scholar 

Dujovne CA, Bays H, Davidson MH, Knopp R, Hunninghake DB, Stein EA, et al. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001;41(1):70–8.

Article  CAS  PubMed  Google Scholar 

Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24(8):729–41.

Article  CAS  PubMed  Google Scholar 

Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.

Article  PubMed  Google Scholar 

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372(25):2387–97.

Article  CAS  PubMed  Google Scholar 

Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Article  Google Scholar 

Laufs U, Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J. 2014;35(30):1996–2000.

Article  PubMed  Google Scholar 

Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimibe lipid-lowering trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or older (EWTOPIA 75): a Randomized, Controlled Trial. Circulation. 2019;140(12):992–1003.

Article  CAS  PubMed  Google Scholar 

Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin. 2006;22(3):511–28.

Article  CAS  PubMed  Google Scholar 

Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80(5):587–95.

Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–61.

Article  CAS  PubMed  Google Scholar 

Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin. 2011;27(6):1191–210.

Article  CAS  PubMed  Google Scholar 

Lee J, Egolum U, Parihar H, Cooley M, Ling H. Effect of Ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels: a Meta-analysis. Cardiol Res. 2021;12(2):98–108.

Article  PubMed  PubMed Central  Google Scholar 

Ezhov MV, Sergienko IV, Kryzhanovskiy SM, Manko KS, Timoshina EV. Comparative efficacy and safety of statin monotherapy and statin plus Ezetimibe combination in a real-world setting. Diseases. 2023;11(4).

Lee J, Lee SH, Kim H, Lee SH, Cho JH, Lee H, et al. Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: real-world evidence. J Clin Pharm Ther. 2021;46(1):134–42.

Article  CAS